SCHEMBL6724092

SCHEMBL6724092

NC1=CCC=C1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18258290 0.79
SCHEMBL25119294 0.79
SCHEMBL1687971 0.71
SCHEMBL1654819 0.69
SCHEMBL19019557 0.69
SCHEMBL23430392 0.67
SCHEMBL1533841 0.65 PPARA (0.32)
SCHEMBL13559270 0.61
SCHEMBL23809710 0.61
SCHEMBL1075123 0.60

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040261198-A1 Restructuring and finishing of keratin fibers HENKEL KOMMANDITGESELLSCHAFT AUF AKTIEN (HENKEL KGAA) (DE) 2004-12-30 US claimed
US-20170333440-A1 TRICYCLIC LACTAMS FOR USE IN HSPC-SPARING TREATMENTS FOR RB-POSITIVE ABNORMAL CELLULAR PROLIFERATION G1 THERAPEUTICS, INC. (US) 2017-11-23 US disclosed
US-9725465-B2 Biaryl acetamide compounds and methods of use thereof AMBIT BIOSCIENCES CORPORATION (US) 2017-08-08 US disclosed
US-9717735-B2 Tricyclic lactams for use in HSPC-sparing treatments for RB-positive abnormal cellular proliferation G1 THERAPEUTICS, INC. (US) 2017-08-01 US disclosed
US-20150299212-A1 Tricyclic Lactams for Use in HSPC-Sparing Treatments for RB-Positive Abnormal Cellular Proliferation G1 THERAPEUTICS, INC. (US) 2015-10-22 US disclosed
US-20150297608-A1 Tricyclic Lactams for Use as Anti-Neoplastic and Anti-Proliferative Agents G1 THERAPEUTICS, INC. (US) 2015-10-22 US disclosed
US-20150297607-A1 Tricyclic Lactams for Use in the Protection of Normal Cells During Chemotherapy G1 THERAPEUTICS, INC. (US) 2015-10-22 US disclosed
US-8987453-B2 Azaadamantane derivatives and methods of use ABBVIE INC. (US) 2015-03-24 US disclosed
US-20150065468-A1 BIARYL ACETAMIDE COMPOUNDS AND METHODS OF USE THEREOF AMBIT BIOSCIENCES CORP (US) 2015-03-05 US disclosed
US-20130096132-A1 AZAADAMANTANE DERIVATIVES AND METHODS OF USE ABBVIE INC. (US) 2013-04-18 US disclosed
US-8314119-B2 Azaadamantane derivatives and methods of use ABBVIE INC. (US) 2012-11-20 US disclosed
US-20110065133-A1 O-ring Systems and Methods for Quantification of Multiplex Biomarkers in Multiple Samples LIU WEIQUN 2011-03-17 US disclosed
US-20080167336-A1 Alzheimer's disease; central nervous system disorders; aids; Pick's disease; attention deficit disorder; hyperactivity; Down's syndrome, amytropic lateral sclerosis; Huntington's disease; suppression of smoking; drug abruse; brain disorders; analgesics; antiinflammatory agents ABBOTT LABORATORIES (US) 2008-07-10 US disclosed
US-20040261198-A1 Restructuring and finishing of keratin fibers HENKEL KOMMANDITGESELLSCHAFT AUF AKTIEN (HENKEL KGAA) (DE) 2004-12-30 US disclosed